Sareum Holdings plc - Revision history

95.149.161.144: /* What are the assumptions used to estimate the return? */

2024-02-25T07:36:02Z

What are the assumptions used to estimate the return?

← Older revision		Revision as of 08:36, 25 February 2024
Line 1,898:		Line 1,898:
	\|-		\|-
	\|Discount rate (%)		\|Discount rate (%)
	\|15%		\|5.98%
	\|There are two key risk parameters for a firm that need to be estimated: its cost of equity and its cost of debt. A key way to estimate the cost of equity is by looking at the beta (or betas) of the company in question, the cost of debt from a measure of default risk (an actual or synthetic rating) and apply the market value weights for debt and equity to come up with the cost of capital.		\|There are two key risk parameters for a firm that need to be estimated: its cost of equity and its cost of debt. A key way to estimate the cost of equity is by looking at the beta (or betas) of the company in question, the cost of debt from a measure of default risk (an actual or synthetic rating) and apply the market value weights for debt and equity to come up with the cost of capital.
	\|-		\|-

95.149.161.144: /* Cost of equity */

2024-02-25T07:18:16Z

Cost of equity

← Older revision		Revision as of 08:18, 25 February 2024
Line 1,836:		Line 1,836:
	=Risks=		=Risks=

	As with any investment, investing in ~~Tesla~~ carries a level of risk. Overall, based on the Sareum's adjusted beta (i.e. 0.25), the degree of risk associated with an investment in Sareum is 'low'.		As with any investment, investing in Sareum carries a level of risk. Overall, based on the Sareum's adjusted beta (i.e. 0.25), the degree of risk associated with an investment in Sareum is 'low'.

	Here, to estimate the adjusted beta, we used the iShares MSCI World ETF to represent the market portfolio; and in terms of the time period and frequency of observations, we used five years of monthly data (i.e. 60 observations in total), which is supported by a study and is the most common choice. The beta value in a future period has been found to be on average closer to the mean value of 1.0, and because valuation is forward-looking, it is logical to adjust the raw beta so it more accurately predicts a future beta. In addition, here, we have assumed that for an investment to be considered 'low' risk, it must have a beta value of less than 0.5. Further information about the beta ratings can be found in the appendix section of this report.		Here, to estimate the adjusted beta, we used the iShares MSCI World ETF to represent the market portfolio; and in terms of the time period and frequency of observations, we used five years of monthly data (i.e. 60 observations in total), which is supported by a study and is the most common choice. The beta value in a future period has been found to be on average closer to the mean value of 1.0, and because valuation is forward-looking, it is logical to adjust the raw beta so it more accurately predicts a future beta. In addition, here, we have assumed that for an investment to be considered 'low' risk, it must have a beta value of less than 0.5. Further information about the beta ratings can be found in the appendix section of this report.

	The key risks can be found below. For us, currently, the biggest risk to the valuation of the company relates to ~~the~~ unfavourable outcomes from its clinical trials (i.e. clinical trials risk).		The key risks can be found below. For us, currently, the biggest risk to the valuation of the company relates to unfavourable outcomes from its clinical trials (i.e. clinical trials risk).

	==Drug development risk==		==Drug development risk==
Line 2,299:		Line 2,299:
	\|		\|
	\|}		\|}

	~~=== Cost of equity ===~~

	=== Cost of equity ===		=== Cost of equity ===
Line 2,324:		Line 2,322:
	\|5.98%		\|5.98%
	\|Cost of equity = Risk-free rate + Beta x Equity risk premium.		\|Cost of equity = Risk-free rate + Beta x Equity risk premium.
			\|}

			=== Beta risk profile ===
			{\| class="wikitable"
			\|+
			!Beta value
			!Risk rating
			\|-
			\|style="background: green; color: white;" \|0 to 0.50
			\|style="background: green; color: white;" \| Low
			\|-
			\|style="background: orange; color: white;" \| 0.50 to 1.50
			\|style="background: orange; color: white;" \| Medium
			\|-
			\|style="background: red; color: white;" \| 1.50 to 3.00
			\|style="background: red; color: white;" \| High
			\|-
			\|style="background: purple; color: white;" \| 3.00 and above
			\|style="background: purple; color: white;" \| Extremely high
	\|}		\|}

95.149.161.144: /* Risks */

2024-02-25T07:05:46Z

Risks

Show changes

95.149.161.144: /* Competition */

2024-02-24T22:56:41Z

Competition

← Older revision		Revision as of 23:56, 24 February 2024
Line 39:		Line 39:
	Sareum Holdings plc operates in the biotech and pharmaceutical market, focusing on the discovery and development of innovative drugs for cancer and autoimmune diseases. Its market can be further segmented as follows:		Sareum Holdings plc operates in the biotech and pharmaceutical market, focusing on the discovery and development of innovative drugs for cancer and autoimmune diseases. Its market can be further segmented as follows:

	# Oncology Market: Sareum focuses on developing therapies targeting cancers with significant unmet medical needs. The company seeks to address various forms of cancer through its drug development programs.		# Oncology Market: Sareum focuses on developing therapies targeting cancers with significant unmet medical needs. The company seeks to address various forms of cancer through its drug development programs.
	# Autoimmune Disease Therapeutics Market: Sareum is also engaged in creating treatments for immune-mediated diseases, tapping into the growing demand for new and effective autoimmune therapies.		# Autoimmune Disease Therapeutics Market: Sareum is also engaged in creating treatments for immune-mediated diseases, tapping into the growing demand for new and effective autoimmune therapies.
	# Research and Development: Sareum operates in the R&D sector of pharma, with its efforts in early-stage discovery and partnerships with other pharmaceutical entities to further drug development and commercialisation.		# Research and Development: Sareum operates in the R&D sector of pharma, with its efforts in early-stage discovery and partnerships with other pharmaceutical entities to further drug development and commercialisation.
Line 47:		Line 47:
	=Competition=		=Competition=

	~~As of my last update,~~ Sareum Holdings plc operates in the biopharmaceutical industry, particularly focusing on the discovery and development of innovative drug candidates aimed at cancers and autoimmune diseases. The competitors of Sareum Holdings plc typically include other biotech and pharmaceutical companies working on similar drug targets or within the same therapeutic areas. Some of these competitors might be:		Sareum Holdings plc operates in the biopharmaceutical industry, particularly focusing on the discovery and development of innovative drug candidates aimed at cancers and autoimmune diseases. The competitors of Sareum Holdings plc typically include other biotech and pharmaceutical companies working on similar drug targets or within the same therapeutic areas. Some of these competitors might be:

	# AstraZeneca plc		# AstraZeneca plc
Line 1,834:		Line 1,834:
	\|		\|
	\|}		\|}


	=Risks=		=Risks=

95.149.161.144: /* Current strategy */

2024-02-24T22:53:46Z

Current strategy

← Older revision		Revision as of 23:53, 24 February 2024
Line 1:		Line 1:
	== Summary ==		== Summary ==

	Sareum Holdings plc is a biopharmaceutical company that ~~specializes~~ in discovering and developing new therapeutic drugs. The company focuses primarily on cancer and autoimmune diseases and is known for leveraging its proprietary drug discovery platform to identify and design new small molecule compounds with therapeutic potential.		Sareum Holdings plc is a biopharmaceutical company that specialises in discovering and developing new therapeutic drugs. The company focuses primarily on cancer and autoimmune diseases and is known for leveraging its proprietary drug discovery platform to identify and design new small molecule compounds with therapeutic potential.

	The company is based in the United Kingdom and operates mainly in the pre-clinical and early clinical phases of drug development. Sareum seeks to partner with larger pharmaceutical ~~organizations~~ to advance its compounds through the development pipeline and into ~~commercialization~~.		The company is based in the United Kingdom and operates mainly in the pre-clinical and early clinical phases of drug development. Sareum seeks to partner with larger pharmaceutical organisations to advance its compounds through the development pipeline and into commercialisation.

	=Operations=		=Operations=
Line 9:		Line 9:
	==How the idea of the company came about?==		==How the idea of the company came about?==

	Sareum Holdings plc was ~~conceptualized~~ from the aim to discover and develop innovative therapeutic drugs for cancer and autoimmune diseases. It emerged from the identification of the need for more targeted and effective treatments within these widespread and impactful health conditions.		Sareum Holdings plc was conceptualised from the aim to discover and develop innovative therapeutic drugs for cancer and autoimmune diseases. It emerged from the identification of the need for more targeted and effective treatments within these widespread and impactful health conditions.

	==Mission==		==Mission==
Line 19:		Line 19:
	# Discovery and development of innovative small molecule drugs.		# Discovery and development of innovative small molecule drugs.
	# Therapies targeting cancer and autoimmune diseases.		# Therapies targeting cancer and autoimmune diseases.
	# Partnership opportunities for co-development and ~~commercialization~~ of ~~their~~ drug candidates.		# Partnership opportunities for co-development and commercialisation of its drug candidates.
	# Research and development services to identify and develop kinase inhibitors.		# Research and development services to identify and develop kinase inhibitors.

	==Current strategy==		==Current strategy==

	The current strategy of Sareum Holdings plc revolves around advancing ~~their~~ lead drug development programs to clinical trials, securing partnerships with pharmaceutical entities to enhance development and ~~commercializing~~ efforts, and continuing research to expand ~~their~~ portfolio of therapeutic candidates.		The current strategy of Sareum Holdings plc revolves around advancing its lead drug development programs to clinical trials, securing partnerships with pharmaceutical entities to enhance development and commercialising efforts, and continuing research to expand its portfolio of therapeutic candidates.

	==Team==		==Team==
Line 37:		Line 37:
	=Market=		=Market=

	Sareum Holdings plc operates in the biotech and pharmaceutical market, focusing on the discovery and development of innovative drugs for cancer and autoimmune diseases. ~~Their~~ market can be further segmented as follows:		Sareum Holdings plc operates in the biotech and pharmaceutical market, focusing on the discovery and development of innovative drugs for cancer and autoimmune diseases. Its market can be further segmented as follows:

	# Oncology Market: Sareum focuses on developing therapies targeting cancers with significant unmet medical needs. The company seeks to address various forms of cancer through its drug development programs.		# Oncology Market: Sareum focuses on developing therapies targeting cancers with significant unmet medical needs. The company seeks to address various forms of cancer through its drug development programs.
	# Autoimmune Disease Therapeutics Market: Sareum is also engaged in creating treatments for immune-mediated diseases, tapping into the growing demand for new and effective autoimmune therapies.		# Autoimmune Disease Therapeutics Market: Sareum is also engaged in creating treatments for immune-mediated diseases, tapping into the growing demand for new and effective autoimmune therapies.
	# Research and Development: Sareum operates in the R&D sector of pharma, with its efforts in early-stage discovery and partnerships with other pharmaceutical entities to further drug development and ~~commercialization~~.		# Research and Development: Sareum operates in the R&D sector of pharma, with its efforts in early-stage discovery and partnerships with other pharmaceutical entities to further drug development and commercialisation.

	Its target market is global, with a focus on regions that have strong patent protections and established regulatory frameworks for drug approval, such as the United States, Europe, and parts of Asia. As Sareum's products progress through clinical trials, ~~their~~ market potential also includes partnerships with larger pharma companies for further development and distribution.		Its target market is global, with a focus on regions that have strong patent protections and established regulatory frameworks for drug approval, such as the United States, Europe, and parts of Asia. As Sareum's products progress through clinical trials, its market potential also includes partnerships with larger pharma companies for further development and distribution.

	=Competition=		=Competition=
Line 59:		Line 59:
	# Blueprint Medicines Corporation		# Blueprint Medicines Corporation

	It is important to note, however, that the competitive landscape is dynamic and can change as companies progress through drug development, achieve regulatory approvals, form strategic partnerships, or shift ~~their~~ research focus.		It is important to note, however, that the competitive landscape is dynamic and can change as companies progress through drug development, achieve regulatory approvals, form strategic partnerships, or shift its research focus.

	=Financials=		=Financials=
Line 1,844:		Line 1,844:
	1. Clinical Trials: The success of Sareum relies heavily on the results of clinical trials. Unfavorable outcomes can impact the company's value.		1. Clinical Trials: The success of Sareum relies heavily on the results of clinical trials. Unfavorable outcomes can impact the company's value.

	2. Regulatory Approval: There is no guarantee that Sareum's products will receive the necessary regulatory approvals, which are essential for ~~commercialization~~.		2. Regulatory Approval: There is no guarantee that Sareum's products will receive the necessary regulatory approvals, which are essential for commercialisation.

	==Financial risk==		==Financial risk==
Line 1,855:		Line 1,855:
	1. Market Competition: Sareum operates in a highly competitive industry, and any advances by competitors can impact its market position.		1. Market Competition: Sareum operates in a highly competitive industry, and any advances by competitors can impact its market position.

	2. Market Penetration: Successfully ~~commercializing~~ products requires effective marketing and sales strategies, which can be challenging for smaller companies.		2. Market Penetration: Successfully commercialising products requires effective marketing and sales strategies, which can be challenging for smaller companies.

	==Intellectual property risk==		==Intellectual property risk==

95.149.161.144: /* Financials */

2024-02-24T22:42:30Z

Financials

← Older revision		Revision as of 23:42, 24 February 2024
Line 1,558:		Line 1,558:
	\|$8,000-15,000		\|$8,000-15,000
	\|-		\|-
	\|Animal Studies Phase 1		\|Animal Studies Phase 2
	\|$1,000,000		\|$1,000,000
	\|		\|
Line 1,584:		Line 1,584:
	\|$4,000-7,500		\|$4,000-7,500
	\|-		\|-
	\|Animal Studies Phase 1		\|Animal Studies Phase 3
	\|$1,500,000		\|$1,500,000
	\|		\|
Line 1,623:		Line 1,623:
	\|-		\|-
	\|Patient Population		\|Patient Population
	\|		\|2,000,000
	\|		\|
	\|-		\|-
	\|Annual Revenue Per Patient		\|Annual Revenue Per Patient
	\|		\|$13,000
	\|		\|
	\|-		\|-
	\|Peak Market Penetration		\|Peak Market Penetration
	\|		\|3%
	\|		\|
	\|-		\|-
	\|Patient Polpulation Growth Rate		\|Patient Polpulation Growth Rate
	\|		\|2%
	\|		\|
	\|-		\|-
Line 1,726:		Line 1,726:
	\|$8,000-15,000		\|$8,000-15,000
	\|-		\|-
	\|Animal Studies Phase 1		\|Animal Studies Phase 2
	\|$1,000,000		\|$1,000,000
	\|		\|
Line 1,752:		Line 1,752:
	\|$4,000-7,500		\|$4,000-7,500
	\|-		\|-
	\|Animal Studies Phase 1		\|Animal Studies Phase 3
	\|$1,500,000		\|$1,500,000
	\|		\|
Line 1,791:		Line 1,791:
	\|-		\|-
	\|Patient Population		\|Patient Population
	\|		\|2,000,000
	\|		\|
	\|-		\|-
	\|Annual Revenue Per Patient		\|Annual Revenue Per Patient
	\|		\|$13,000
	\|		\|
	\|-		\|-
	\|Peak Market Penetration		\|Peak Market Penetration
	\|		\|3%
	\|		\|
	\|-		\|-
	\|Patient Polpulation Growth Rate		\|Patient Polpulation Growth Rate
	\|		\|2%
	\|		\|
	\|-		\|-

95.149.161.144 at 22:31, 24 February 2024

2024-02-24T22:31:09Z

Show changes

95.149.161.144 at 22:09, 24 February 2024

2024-02-24T22:09:52Z

Show changes

95.149.161.144: Undo revision 10488175 by 95.149.161.144 (talk)

2024-02-24T22:00:02Z

Undo revision 10488175 by 95.149.161.144 (talk)

Show changes

95.149.161.144: Undo revision 10488174 by 95.149.161.144 (talk)

2024-02-24T21:59:44Z

Undo revision 10488174 by 95.149.161.144 (talk)

Show changes